

Global Congenital Adrenal Hyperplasia Treatment Market Report and Forecast 2023-2031

Market Report | 2023-04-13 | 147 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Congenital Adrenal Hyperplasia Treatment Market Report and Forecast 2023-2031

Global Congenital Adrenal Hyperplasia Treatment Market Outlook

The growth of the global congenital adrenal hyperplasia treatment market is being driven by the increasing prevalence of the condition worldwide and the growing investment in research and development activities. The global congenital adrenal hyperplasia is likely to grow at a rate of 7.75% during the forecast period of 2023-2031.

Congenital Adrenal Hyperplasia Treatment Market: Introduction

Global congenital adrenal hyperplasia treatment market report by Expert Market Research provides an in-depth analysis of the market and its segments. Congenital adrenal hyperplasia is a group of genetic disorders that affect the adrenal glands, causing an insufficient production of essential hormones. Treatment options for congenital adrenal hyperplasia include medication, hormone replacement therapy, and surgery. The report covers the market for congenital adrenal hyperplasia treatment and provides a detailed analysis of the market size, growth, and trends.

The congenital adrenal hyperplasia treatment market is expected to witness significant advancements in the coming years. The development of novel therapies, such as gene therapy, and the increasing focus on personalized medicine are likely to drive the growth of the market. Additionally, the expansion of healthcare infrastructure in emerging economies and the increasing demand for advanced diagnostic tools and treatment options are expected to create lucrative opportunities for the market players.

Moreover, the growing adoption of telemedicine and digital health technologies may provide new avenues for the management and treatment of CONGENITAL ADRENAL HYPERPLASIA, potentially improving patient outcomes and reducing healthcare costs. As a result, the global CONGENITAL ADRENAL HYPERPLASIA treatment market is expected to continue its growth trajectory throughout the forecast period, offering numerous opportunities for key players and investors in the industry.

Congenital Adrenal Hyperplasia Epidemiology

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The global epidemiology of congenital adrenal hyperplasia varies based on factors such as ethnicity, geographic location, and the type of congenital adrenal hyperplasia. Improved awareness, new-born screening programs, and further epidemiological studies are crucial to better understand the distribution and determinants of congenital adrenal hyperplasia, which can aid in the development of more effective treatments and prevention strategies.

Congenital adrenal hyperplasia affects approximately 1 in 10,000 to 18,000 live births worldwide, with varying prevalence based on ethnicity and geographic region. The most common form of congenital adrenal hyperplasia is 21-hydroxylase deficiency, accounting for over 90% of cases. Early diagnosis and appropriate treatment are crucial in managing the condition and preventing complications.

Congenital Adrenal Hyperplasia Treatment Market Segmentations

The market can be categorised into diagnosis method, treatment method, therapeutic channel, and region.

Market Breakup by Diagnosis Method

- Prenatal Testing
- ?□Amniocentesis
- ?□Chorionic Villus Sampling
- Physical Exam
- Blood and Urine Tests
- Genetic Testing

Market Breakup by Treatment Method

- Medication
- Medications
- Physical Exams
- Reconstructive Surgery

Market Breakup by Therapeutic Channel

- Public
- Private

Market Breakup by Region

- North America
- ?□United States of America
- ?□Canada
- Europe
- ?□United Kingdom
- ?□Germany
- ?□France
- ?□Italy
- ?□Others
- Asia Pacific
- ?□China
- ?□Japan
- ?□India
- ?□ASEAN
- ?□Australia
- ?□Others
- Latin America
- ?□Brazil
- ?□Argentina
- ?□Mexico
- ?□Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Middle East and Africa
- ?□Saudi Arabia
- ?□United Arab Emirates
- ?□Nigeria
- ?□South Africa
- ?□Others

Congenital Adrenal Hyperplasia Treatment Market Scenario

The market is expected to grow at a significant rate during the forecast period of 2023-2031. The increasing prevalence of the disease, rising awareness, and growing investment in research and development activities are the key drivers of the market. North America dominates the market, followed by Europe and Asia Pacific. The leading players in the market are focusing on the development of new drugs and therapies and adopting various strategies to strengthen their position in the market. North America dominates the congenital adrenal hyperplasia treatment market, followed by Europe and Asia Pacific. The high prevalence of congenital adrenal hyperplasia in North America, coupled with the favourable reimbursement policies, is driving the growth of the market in the region. Europe is also a significant market for congenital adrenal hyperplasia treatment, with the presence of key players and increasing investment in research and development activities. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about the disease and the rising healthcare expenditure in the region.

Key Players in the Global Congenital Adrenal Hyperplasia Treatment Market

The report gives an in-depth analysis of the key players involved in the congenital adrenal hyperplasia treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

- Neurocrine Bioscience
- Johnson and Johnson
- Sanofi
- Zydus Lifesciences Ltd.
- GSK plc
- BridgeBio, Inc.
- Millendo Therapeutics, Inc.
- Spruce Biosciences
- EffRx Pharmaceuticals

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.1.1 Research Objectives
 - 1.1.2 Key Findings of the Report
 - 1.2 Limitations of the Study and Scope for Future Research
- 2 Research Methodology
- 3 Executive Summary
- 4 Global Congenital Adrenal Hyperplasia Treatment Disease Overview
 - 4.1 Guidelines and Stages

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.2 Pathophysiology
- 4.3 Screening and Diagnosis
- 4.4 Treatment Pathway
- 5 Patient Profile
 - 5.1 Patient Profile Model
 - 5.2 Patient Psychology and Emotional Impact Factors
 - 5.3 Risk Assessment and Treatment Success Rate
- 6 Global Congenital Adrenal Hyperplasia Treatment Market
 - 6.1 Global Congenital Adrenal Hyperplasia Treatment Market Overview
 - 6.2 Global Congenital Adrenal Hyperplasia Treatment Market Analysis
 - 6.2.1 Market Overview
 - 6.2.1.1 Global Historical Congenital Adrenal Hyperplasia Treatment Market Volume (2016-2022)
 - 6.2.1.2 Global Forecast Congenital Adrenal Hyperplasia Treatment Market Volume (2023-2031)
 - 6.2.2 Global Congenital Adrenal Hyperplasia Treatment Market by Diagnosis Method
 - 6.2.2.1 Market Overview
 - 6.2.2.1.1 Prenatal Testing
 - 6.2.2.1.1.1 Amniocentesis
 - 6.2.2.1.1.2 Chorionic Villus Sampling
 - 6.2.2.1.2 Physical Exam
 - 6.2.2.1.3 Blood and Urine Tests
 - 6.2.2.1.4 Genetic Testing
 - 6.2.3 Global Congenital Adrenal Hyperplasia Treatment Market by Treatment Method
 - 6.2.3.1 Market Overview
 - 6.2.3.1.1 Medications
 - 6.2.3.1.2 Physical Exams
 - 6.2.3.1.3 Reconstructive Surgery
 - 6.3 Global Congenital Adrenal Hyperplasia Treatment Market by Therapeutic Channel
 - 6.3.1 Market Overview
 - 6.3.1.1 Public
 - 6.3.1.2 Private
 - 6.4 Global Congenital Adrenal Hyperplasia Treatment Market by Region
 - 6.4.1 Market Overview
 - 6.4.1.1 North America
 - 6.4.1.1.1 Historical Trend (2016-2022)
 - 6.4.1.1.2 Forecast Trend (2023-2031)
 - 6.4.1.2 Europe
 - 6.4.1.2.1 Historical Trend (2016-2022)
 - 6.4.1.2.2 Forecast Trend (2023-2031)
 - 6.4.1.3 Asia Pacific
 - 6.4.1.3.1 Historical Trend (2016-2022)
 - 6.4.1.3.2 Forecast Trend (2023-2031)
 - 6.4.1.4 Latin America
 - 6.4.1.4.1 Historical Trend (2016-2022)
 - 6.4.1.4.2 Forecast Trend (2023-2031)
 - 6.4.1.5 Middle East and Africa
 - 6.4.1.5.1 Historical Trend (2016-2022)
 - 6.4.1.5.2 Forecast Trend (2023-2031)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7 North America Congenital Adrenal Hyperplasia Treatment Market
 - 7.1 United States of America
 - 7.1.1 Historical Trend (2016-2022)
 - 7.1.2 Forecast Trend (2023-2031)
 - 7.2 Canada
 - 7.2.1 Historical Trend (2016-2022)
 - 7.2.2 Forecast Trend (2023-2031)
- 8. Europe Congenital Adrenal Hyperplasia Treatment Market
 - 8.1 United Kingdom
 - 8.1.1 Historical Trend (2016-2022)
 - 8.1.2 Forecast Trend (2023-2031)
 - 8.2 Germany
 - 8.2.3 Historical Trend (2016-2022)
 - 8.2.4 Forecast Trend (2023-2031)
 - 8.3 France
 - 8.3.1 Historical Trend (2016-2022)
 - 8.3.2 Forecast Trend (2023-2031)
 - 8.4 Italy
 - 8.4.1 Historical Trend (2016-2022)
 - 8.4.2 Forecast Trend (2023-2031)
- 9 Asia Pacific Congenital Adrenal Hyperplasia Treatment Market
 - 9.1 China
 - 9.1.1 Historical Trend (2016-2022)
 - 9.1.2 Forecast Trend (2023-2031)
 - 9.2 Japan
 - 9.2.1 Historical Trend (2016-2022)
 - 9.2.2 Forecast Trend (2023-2031)
 - 9.3 India
 - 9.3.1 Historical Trend (2016-2022)
 - 9.3.2 Forecast Trend (2023-2031)
 - 9.4 ASEAN
 - 9.4.1 Historical Trend (2016-2022)
 - 9.4.2 Forecast Trend (2023-2031)
 - 9.5 Australia
 - 9.5.1 Historical Trend (2016-2022)
 - 9.5.2 Forecast Trend (2023-2031)
- 10 Latin America Congenital Adrenal Hyperplasia Treatment Market
 - 10.1 Brazil
 - 10.1.1 Historical Trend (2016-2022)
 - 10.1.2 Forecast Trend (2023-2031)
 - 10.2 Argentina
 - 10.2.1 Historical Trend (2016-2022)
 - 10.2.2 Forecast Trend (2023-2031)
 - 10.3 Mexico
 - 10.3.1 Historical Trend (2016-2022)
 - 10.3.2 Forecast Trend (2023-2031)
- 11 Middle East and Africa Congenital Adrenal Hyperplasia Treatment Market

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.1 Saudi Arabia
 - 11.1.1 Historical Trend (2016-2022)
 - 11.1.2 Forecast Trend (2023-2031)
- 11.2 United Arab Emirates
 - 11.2.1 Historical Trend (2016-2022)
 - 11.2.2 Forecast Trend (2023-2031)
- 11.3 Nigeria
 - 11.3.1 Historical Trend (2016-2022)
 - 11.3.2 Forecast Trend (2023-2031)
- 11.4 South Africa
 - 11.4.1 Historical Trend (2016-2022)
 - 11.4.2 Forecast Trend (2023-2031)
- 12 Current Scenario Evaluation
 - 12.1 Emerging Therapies & Clinical Trials Synopsis
 - 12.2 Patent Landscape
 - 12.2.1 Patent Overview
 - 12.2.1.1 Patent Status and Expiry
 - 12.2.1.2 Timelines from Drug Development to Commercial Launch
 - 12.2.1.3 New Drug Application
 - 12.2.1.3.1 Documentation and Approval Process
 - 12.3 Cost of Treatment
 - 12.4 Regulatory Framework
 - 12.4.1 Regulatory Overview
 - 12.4.1.1 US FDA
 - 12.4.1.2 EU EMA
 - 12.4.1.3 INDIA CDSCO
 - 12.4.1.4 JAPAN PMDA
 - 12.4.1.5 Others
- 13 Challenges & Unmet Needs
 - 13.1 Treatment Pathway Challenges
 - 13.2 Compliance and Drop- out Analysis
 - 13.3 Awareness and Prevention Gaps
- 14 Global Congenital Adrenal Hyperplasia Treatment Market Dynamics
 - 14.1 Market Drivers and Constraints
 - 14.2 SWOT Analysis
 - 14.3 Porter's Five Forces Model
 - 14.4 Key Demand Indicators
 - 14.5 Key Price Indicators
 - 14.6 Market Events, Initiatives & Trends
 - 14.7 Value Chain Analysis
- 15 Supplier Landscape
 - 15.1 Neurocrine Bioscience
 - 15.1.1 Company Overview
 - 15.1.2 Product Portfolio
 - 15.1.3 Demographic Reach and Achievements
 - 15.1.4 Mergers and Acquisitions
 - 15.1.5 Certifications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.2 Johnson and Johnson
 - 15.2.1 Company Overview
 - 15.2.2 Product Portfolio
 - 15.2.3 Demographic Reach and Achievements
 - 15.2.4 Mergers and Acquisitions
 - 15.2.5 Certifications
- 15.3 Sanofi
 - 15.3.1 Company Overview
 - 15.3.2 Product Portfolio
 - 15.3.3 Demographic Reach and Achievements
 - 15.3.4 Mergers and Acquisitions
 - 15.3.5 Certifications
- 15.4 Zydus Lifesciences Ltd.
 - 15.4.1 Company Overview
 - 15.4.2 Product Portfolio
 - 15.4.3 Demographic Reach and Achievements
 - 15.4.4 Mergers and Acquisitions
 - 15.4.5 Certifications
- 15.5 GSK plc
 - 15.5.1 Company Overview
 - 15.5.2 Product Portfolio
 - 15.5.3 Demographic Reach and Achievements
 - 15.5.4 Mergers and Acquisitions
 - 15.5.5 Certifications
- 15.6 BridgeBio, Inc.
 - 15.6.1 Company Overview
 - 15.6.2 Product Portfolio
 - 15.6.3 Demographic Reach and Achievements
 - 15.6.4 Mergers and Acquisitions
 - 15.6.5 Certifications
- 15.7 Millendo Therapeutics, Inc.
 - 15.7.1 Company Overview
 - 15.7.2 Product Portfolio
 - 15.7.3 Demographic Reach and Achievements
 - 15.7.4 Mergers and Acquisitions
 - 15.7.5 Certifications
- 15.8 Spruce Biosciences
 - 15.8.1 Company Overview
 - 15.8.2 Product Portfolio
 - 15.8.3 Demographic Reach and Achievements
 - 15.8.4 Mergers and Acquisitions
 - 15.8.5 Certifications
- 15.9 EffRx Pharmaceuticals
 - 15.9.1 Company Overview
 - 15.9.2 Product Portfolio
 - 15.9.3 Demographic Reach and Achievements
 - 15.9.4 Mergers and Acquisitions

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.9.5 Certifications
- 16 Recommendations and Discussion
- 17 Global Congenital Adrenal Hyperplasia Treatment Distribution Model (Additional Insight)
 - 17.1 Overview
 - 17.2 Potential Distributors
 - 17.3 Key Parameters for Distribution Partner Assessment
- 18 Payment Methods (Additional Insight)
 - 18.1 Government Funded
 - 18.2 Private Insurance
 - 18.3 Out-of-Pocket

Global Congenital Adrenal Hyperplasia Treatment Market Report and Forecast 2023-2031

Market Report | 2023-04-13 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-15"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com
www.scotts-international.com